Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study
University of Udine
90 participants
Apr 22, 2024
OBSERVATIONAL
Conditions
Summary
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.
Eligibility
Inclusion Criteria4
- Age > 18 years
- Fertile age
- Clinical-ultrasound diagnosis or histological diagnosis of endometriosis
- Informed consent
Exclusion Criteria5
- Pregnancy
- Pre-menarcheal or post-menopausal status
- Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)
- Neoplasia, diabetes, BMI > 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement
- Currently undergoing progestin therapy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06414720